Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

BACKGROUND: Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia. Previous clinical studies in melanoma returned inconclusive results and...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoko, Josip, Rožanc, Jan, Charles, Emilie M., Alexopoulos, Leonidas G., Rehm, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307246/
https://www.ncbi.nlm.nih.gov/pubmed/30587121
http://dx.doi.org/10.1186/s12860-018-0180-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307246/
https://www.ncbi.nlm.nih.gov/pubmed/30587121
http://dx.doi.org/10.1186/s12860-018-0180-1

Ejemplares similares